Peace of mind
is in your hands
is in your hands
Assay designed to detect relapse early using circulating tumor DNA (ctDNA). Highly sensitive and personalized for each patient.
OncoTracking™ monitors patients for early signs
of cancer recurrence.
of cancer recurrence.
Molecular residual disease (MRD)
Early Recurrence Monitoring
Track
Our personalized genetic test is informed by the patient’s own tumor mutation signature, making our MRD detection different from traditionally uses of ctDNA*
The sooner cancer recurrence or metastasis is found, the sooner the patient can receive appropriate therapy and treatment.
*Therapy selection and asymptomatic cancer screening
Monitors blood for a specific type of cancer to detect recurrence sooner than traditional test such as CT scans or MRIs.
Expanding molecular profiling
and access to therapy options
and access to therapy options
Higher levels of ctDNA are an immediate indication that malignant cancer may exist in the body. The presence of specific biomarkers helps immediately diagnose the type of disease. For example, using the KRAS biomarker, Bettegowda et al. found metastatic cancer in 82% of patients and localized cancer of all types in 55% of patients. Early cancer detection can reduce morbidity and mortality, leading to treatment such as surgery before the tumor metastasizes. (CREATE graph depicting the highest sensitivities in detecting cancer using ctDNA)
Source link
Source link
Tumors in the body can be tracked in real-time through ctDNA. The use of different drugs or therapies can be influenced by treatment-resistant mutations as well. KRAS codon 61 appears to be associated with acquired resistance, which indicates against cancer treatment with anti-EGFT antibodies (Loupakis, et al.). In further research, Kato et al. These findings suggest that EGFT antibodies may not be effective in treating cancer (Loupakis et al. During radiation treatment, patients with a unique genotype had ectopic ctDNA (genetic material generated exclusively from destroyed cells) in the blood. As a result, the treatment was successful. Patients do not need to suffer through unnecessary pain and ineffective treatment with PT.
A molecular marker can be used in oncology to identify disease patterns when methylation alters the expression of healthy genes. CtDNA methylation patterns are typically associated with origin tumors as a result of methylation. Measurements of biomarkers related to cancer-specific ctDNA methylation can be used to determine prognosis (Warton et al.). EpiproColon can detect colon cancer by monitoring DNA methylation of SEPT9 gene.
Remission patients often need close monitoring for signs of relapse. Biomarkers that indicate the re-emergence of tumors can be identified using ctDNA, a noninvasive, high-specificity method. Additionally, it is useful for categorizing patients based on their recurrence risk. Researchers measured ctDNA levels in people who underwent colorectal cancer surgery in a recent study by Douillard et al. Patients with measurable amounts of ctDNA relapsed 100% of the time, while those with imperceptible amounts remained disease-free.
02
05
01
04
03
How does it work?
Retrieval
Targeting phase
Monitoring phase
Tracking
Analysis
Reports
Customization
Tumor sample is retrieved from facility where surgery was performed
Blood samples drawn every 3 months to track UTMs in the blood
Tumor sample analyzed for Unique Tumor Markers (UTMs) and potential treatment targets
If UTM level is identified, it may suggest that the cancer has returned
Customized assays are created based on the UTMs found in tumor tissue
When is it needed?
When a patient is in remission and would like to track the status of their remission to discover the earliest signs that the cancer may have returned
Get in touch
Get peace of mind, today.